REVIEW
Add like
Add dislike
Add to saved papers

Neovascular glaucoma and intraocular pressure: I. Pathogenesis of increased intraocular pressure and therapy (a review of historical and current therapeutic modalities).

The pathogenesis of neovascular glaucoma is summarized. Elevation of intraocular pressure is mostly associated with mechanical obstruction of the anterior chamber angle by the fibrovascular membrane, as well as with an enhanced ultrafiltration from the newly formed vessels. Drug therapy is insufficient. Standard filtering surgery is unsatisfactory with regard to the control of intraocular pressure and hemorrhagic complications. The drainage implants appear to be promising. Panretinal photocoagulation is unfavorable due to turbidity of the optical media. Favorable therapeutical results were achieved with cryosurgical techniques, namely panretinal cryocoagulation, combined with cyclocryocoagulation. Cyclocryocoagulation alone accounts for a high percentage of complications and therapeutical results are not convincing.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app